Profiles of Leading Women Scientists on AcademiaNet.
Search among the members of the Leopoldina for experts in specific fields or research topics.
Year of election: | 2011 |
Section: | History of Science and Medicine |
City: | Princeton |
Country: | USA |
Research Priorities: Molecular biology and intellectual property in Europe and the US, music, science and technology in the 18th, 19th and 20th century, bioethics, genetic patents, the impact of intellectual property law on research in the areas of molecular genetics, race and genomics.
Myles W. Jackson is an American science historian. His work centres around the historical, philosophical and sociological aspects of science and technology. One his key areas of interest is the cultural history of British and German physics in the 19th century. As part of interdisciplinary investigations, he regularly looks into the aesthetic relationship between music and physics.
His research into the investigator and explorer Joseph Fraunhofer has been endowed with several awards. In this research, Jackson concentrated on the cultural and material environment of the German researcher and inventor. He also retraced how Joseph Fraunhofer became a figurehead for the connection between science and industry during the 19th century.
Another of Jackson’s fields of interest is the contemporary history of biotechnology, in particular the impact which intellectual property rights and the patenting of human genes have on research into molecular biology. This is exemplified in a project looking at the patenting of gene CCR5, and the resulting impact on research into AIDS. Jackson uses the history of this particular gene to describe important aspects and effects on biotechnology, linking aspects of molecular biology with the history of natural science and jurisprudence on the one hand, and sociological and anthropological issues on the other. He is a renowned consultant to American institutions on this issue, for instance by advising the American Civil Liberties Union (ACLU) in connection with their legal case against the gene patents held by Myriad Genetics, an American molecular diagnostics company.